We claim:

1. A combination comprising pure 5-HT_6 receptor antagonist and NMDA receptor antagonist wherein the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

4. The combination as claimed in any one of the claim 1 to 3, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in any one of the claim 1 to 4, wherein the pharmaceutically acceptable salt of memantine is memantine hydrochloride.

6. A combination of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and memantine hydrochloride.

7. The combination as claimed in any one of the claim 1 to 6, for use in the treatment of cognitive disorders in a patient.

8. The use as claimed in claim 7, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

9. A method of treatment of cognitive disorders comprising administering to a patient in need thereof a therapeutically effective amount of the combination as claimed in any one of the claim 1 to 6.

10. The method of treatment as claimed in claim 9, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

11. A compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or pharmaceutically acceptable salt thereof for use in combination with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof for the treatment of Alzheimer's disease in a patient.

12. The compound for use as claimed in claim 11, as an adjunct treatment for Alzheimer's disease in a patient on stable treatment with NMDA receptor antagonist or a pharmaceutically acceptable salt thereof.

13. The compound for use as claimed in claim 12 or claim 13, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

14. The compound for use as claimed in claim 11, wherein the 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

15. A method of treating Alzheimer's disease in a patient comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof and NMDA receptor antagonist or a pharmaceutically acceptable salt thereof.

16. A method of treating Alzheimer's disease in a patient on stable treatment with NMDA receptor antagonist comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

17. The method as claimed in claim 15 or claim 16, wherein the pharmaceutically acceptable salt of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

18. The method as claimed in claim 15 or claim 16, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

19. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

20. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

21. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 25 mg to 125 mg of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

22. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

23. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

24. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

25. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof per day.

26. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the patient is administered 5 mg to 28 mg memantine or a pharmaceutically acceptable salt thereof per day.

27. A pharmaceutical composition comprising the combination as claimed in any one of the claim 1 to 6, and pharmaceutically acceptable excipients or combination thereof.

28. The pharmaceutical composition as claimed in claim 27, for use in the treatment of cognitive disorder selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

29. The pharmaceutical composition as claimed in claim 27 or claim 28, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg.

30. The pharmaceutical composition as claimed in claim 27 or claim 28, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg.

31. The pharmaceutical composition as claimed in claim 27 or claim 28, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg.

32. The pharmaceutical composition as claimed in claim 27 or claim 28, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg or 125 mg.

33. The pharmaceutical composition as claimed in claim 27 or claim 28, wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 5 mg to 40 mg.

34. The method of treating Alzheimer's disease as claimed in claim 15 or claim 16, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient by oral, nasal, local, dermal or parenteral routes.

35. The method of treating Alzheimer's disease as claimed in claim 14, wherein the 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient one to three times per day, one to three times per week or one to three times per month.